BackgroundIn breast cancer, immunohistochemical assessment of proliferation using the marker Ki67 has potential use in both research and clinical management. However, lack of consistency across laboratories has limited Ki67's value. A working group was assembled to devise a strategy to harmonize Ki67 analysis and increase scoring concordance. Toward that goal, we conducted a Ki67 reproducibility study.MethodsEight laboratories received 100 breast cancer cases arranged into 1-mm core tissue microarrays-one set stained by the participating laboratory and one set stained by the central laboratory, both using antibody MIB-1. Each laboratory scored Ki67 as percentage of positively stained invasive tumor cells using its own method. Six laboratori...
Introduction: Tumor cell proliferation in breast cancer is strongly prognostic and may also predict ...
Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist's assessm...
Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist's assessm...
BackgroundIn breast cancer, immunohistochemical assessment of proliferation using the marker Ki67 ha...
BACKGROUND: In breast cancer, immunohistochemical assessment of proliferation using the marker Ki67 ...
Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential us...
Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in br...
Although an important biomarker in breast cancer, Ki67 lacks scoring standardization, which has limi...
Although an important biomarker in breast cancer, Ki67 lacks scoring standardization, which has limi...
Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in br...
Ki67 labeling index (LI) is used as a predictive marker and is associated with prognosis in breast c...
<div><p>Background</p><p>Ki67 labeling index (LI) is used as a predictive marker and is associated w...
Background Postanalytic issues of Ki67 assessment in breast cancers like counting method standardisa...
Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential us...
Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment...
Introduction: Tumor cell proliferation in breast cancer is strongly prognostic and may also predict ...
Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist's assessm...
Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist's assessm...
BackgroundIn breast cancer, immunohistochemical assessment of proliferation using the marker Ki67 ha...
BACKGROUND: In breast cancer, immunohistochemical assessment of proliferation using the marker Ki67 ...
Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential us...
Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in br...
Although an important biomarker in breast cancer, Ki67 lacks scoring standardization, which has limi...
Although an important biomarker in breast cancer, Ki67 lacks scoring standardization, which has limi...
Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in br...
Ki67 labeling index (LI) is used as a predictive marker and is associated with prognosis in breast c...
<div><p>Background</p><p>Ki67 labeling index (LI) is used as a predictive marker and is associated w...
Background Postanalytic issues of Ki67 assessment in breast cancers like counting method standardisa...
Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential us...
Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment...
Introduction: Tumor cell proliferation in breast cancer is strongly prognostic and may also predict ...
Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist's assessm...
Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist's assessm...